Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Anticuerpos para terapia antiviral

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20170516001
Publicado:
01/06/2017
Caducidad:
01/06/2018
Resumen:
Una universidad alemana ha desarrollado un procedimiento para estimular anticuerpos que promueve la respuesta celular antiviral. Puesto que existen pocas terapias antivirales directas, el procedimiento de estimulación es una alternativa válida o enfoque terapéutico adicional. La universidad busca compañías farmacéuticas con el fin de establecer acuerdos de licencia.

Details

Tittle:
Antibodies for anti-viral therapy.
Summary:
A German university has developed a procedure to stimulate antibodies that promote the anti-viral T cell response. Since only very few direct anti-viral therapeutics are available, the stimulation procedure is a valid alternative or additional therapeutic approach. The university offers a license agreement to pharmaceutical companies.
Description:
Cytotoxic CD8-positive T cells constitute the crucial leukocyte subpopulation for a cellular response against viral infection. Since only very few direct anti-viral therapeutics are available, the stimulation of an efficient and specific immune response against a viral infection is a valid alternative or additional therapeutic approach. The first of such strategies has been established by use of high doses of interferon, which however has a high risk of adverse reactions of the immune system, and low response rates. Therefore, it is mandatory to search for further immune stimulatory strategies that more specifically induce an anti-viral T cell response.

The herein described approach of a German university is based on an antibody-mediated stimulation of the carcino-embryonic antigen-related cell adhesion molecule 1 (CEACAM1), which activates early parts of both the B cell and T cell receptor-induced signal transduction.
The researchers have shown on the example of the lymphocytic choriomeningitis virus (LCMV) that these antibodies stimulate the activation and expansion of virus specific cytotoxic T cells, which comes along with a reduced virus load in serum and organs of mice. In vitro studies confirmed efficacy also against the influenza virus and cytomegalovirus.

The monoclonal, humanized anti-CEACAM1 antibodies are offered under license agreement to partners from the pharmaceutical sector, who are interested in applying the method.
Advantages and Innovations:
The procedure presented here is a novelty in antibody research. For the first time a therapy approach is stimulating an immune response to a viral infection. It is conceivable as a monotherapy or in combination with other anti-viral therapies.
Other advantages are:
· Applies to a broad range of viruses
· Specific immune response against specific viruses to biogas / methane without inhibition risks
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European and US-American

Partner sought

Type and Role of Partner Sought:
The university is looking for partners from the pharmaceutical industry who are interested in applying the method and is offering them a license agreement.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos
06001018 Virus, virología / antibióticos / bacteriología